Allspring Global Investments Holdings LLC Buys 49,331 Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH)

Allspring Global Investments Holdings LLC increased its position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 3.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,624,501 shares of the company's stock after acquiring an additional 49,331 shares during the quarter. Allspring Global Investments Holdings LLC owned about 3.29% of Prestige Consumer Healthcare worth $126,274,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. nVerses Capital LLC raised its holdings in Prestige Consumer Healthcare by 200.0% in the 3rd quarter. nVerses Capital LLC now owns 600 shares of the company's stock worth $43,000 after acquiring an additional 400 shares during the period. Huntington National Bank raised its holdings in Prestige Consumer Healthcare by 39.9% in the 3rd quarter. Huntington National Bank now owns 635 shares of the company's stock worth $46,000 after acquiring an additional 181 shares during the period. International Assets Investment Management LLC raised its holdings in Prestige Consumer Healthcare by 7,112.5% in the 3rd quarter. International Assets Investment Management LLC now owns 1,154 shares of the company's stock worth $83,000 after acquiring an additional 1,138 shares during the period. GAMMA Investing LLC raised its holdings in Prestige Consumer Healthcare by 49.9% in the 3rd quarter. GAMMA Investing LLC now owns 1,163 shares of the company's stock worth $84,000 after acquiring an additional 387 shares during the period. Finally, Covestor Ltd raised its holdings in Prestige Consumer Healthcare by 95.6% in the 3rd quarter. Covestor Ltd now owns 1,338 shares of the company's stock worth $96,000 after acquiring an additional 654 shares during the period. Institutional investors own 99.95% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on PBH. Raymond James upgraded shares of Prestige Consumer Healthcare to a "moderate buy" rating in a report on Thursday, December 19th. Sidoti downgraded shares of Prestige Consumer Healthcare from a "buy" rating to a "neutral" rating and set a $90.00 price objective on the stock. in a report on Monday, December 9th. DA Davidson boosted their price objective on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the stock a "buy" rating in a report on Friday, February 7th. Oppenheimer boosted their price objective on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an "outperform" rating in a report on Thursday. Finally, Canaccord Genuity Group boosted their price objective on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a report on Friday, February 7th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $92.60.

Insider Buying and Selling at Prestige Consumer Healthcare

In other Prestige Consumer Healthcare news, CEO Ronald M. Lombardi sold 10,875 shares of the business's stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the transaction, the chief executive officer now directly owns 320,952 shares in the company, valued at $26,510,635.20. The trade was a 3.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 1.60% of the company's stock.

Prestige Consumer Healthcare Price Performance

Shares of Prestige Consumer Healthcare stock traded down $0.06 during trading on Friday, hitting $85.62. 276,586 shares of the company's stock traded hands, compared to its average volume of 288,972. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.10. The firm's fifty day moving average price is $79.27 and its 200 day moving average price is $75.87. Prestige Consumer Healthcare Inc. has a twelve month low of $62.35 and a twelve month high of $88.36. The company has a market cap of $4.23 billion, a PE ratio of 20.05, a PEG ratio of 2.43 and a beta of 0.50.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last issued its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.